Exome sequencing for paediatric-onset diseases: impact of the extensive involvement of medical geneticists in the diagnostic odyssey by Mak, C.C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/196384
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
ARTICLE OPEN
Exome sequencing for paediatric-onset diseases: impact of the
extensive involvement of medical geneticists in the diagnostic
odyssey
Christopher CY Mak 1, Gordon KC Leung1, Gary TK Mok1, Kit San Yeung1, Wanling Yang1, Cheuk-Wing Fung1,2, Sophelia HS Chan1,2,
So-Lun Lee1,2, Ni-Chung Lee3, Rolph Pfundt4, Yu-Lung Lau1 and Brian HY Chung1,2,5
Currently, offering whole-exome sequencing (WES) via collaboration with an external laboratory is increasingly common. However,
the receipt of a WES report can be merely the beginning of a continuing exploration process rather than the end of the diagnostic
odyssey. The laboratory often does not have the information the physician has, and any discrepancies in variant interpretation must
be addressed by a medical geneticist. In this study, we performed diagnostic WES of 104 patients with paediatric-onset genetic
diseases. The post-exome review of WES reports by the clinical geneticist led to a more comprehensive assessment of variant
pathogenicity in 16 cases. The overall diagnostic yield was 41% (n= 43). Among these 43 diagnoses, 51% (22/43) of the pathogenic
variants were nucleotide changes that have not been previously reported. The time required for the post-exome review of the WES
reports varied, and 26% (n= 27) of the reports required an extensive amount of time (>3 h) for the geneticist to review. In this
predominantly Chinese cohort, we highlight the importance of discrepancies between global and ethnic-speciﬁc frequencies of a
genetic variant that complicate variant interpretation and the signiﬁcance of post-exome diagnostic modalities in genetic diagnosis
using WES. The challenges faced by geneticists in interpreting WES reports are also discussed.
npj Genomic Medicine  (2018) 3:19 ; doi:10.1038/s41525-018-0056-5
INTRODUCTION
Previous multiple large (n > 500) exome projects have reported
yields of 25–30%.1,2 Subsequent reports have increased the yield
to 43%3 and even up to 57.7% in selected groups of patients with
suspected monogenic disorders.4 Most previous studies have
been based on data from large centres or consortiums specialising
in diagnostic exome sequencing,1,5,6 but few studies have focused
on the involvement of the medical geneticist in the diagnostic
process. Baldridge et al.3 published a key study that comprehen-
sively examined the role of the medical geneticist. These authors
reported an increase in the diagnostic yield from 36 to 43% after
an assessment was performed by a geneticist in a cohort in which
minority populations were under-represented. Importantly, the
authors found that non-Caucasians had a lower diagnostic yield
than Caucasians. This difference was statistically signiﬁcant even
after adjusting for the higher rate of craniofacial anomalies. Thus,
we sought to validate this observed low diagnostic yield in non-
Caucasians.
The receipt of a WES report can be merely the beginning of a
continuing exploration process rather than the end of the
diagnostic odyssey. For example, various post-exome diagnostic
modalities may be necessary, such as biochemical analyses,
imaging studies, and complementary molecular tests. Outside of
large institutions specialising in genomics, offering WES via
collaboration with an external service laboratory is increasingly
common. The laboratory and clinical teams may not be
geographically co-located, leading to further challenges. The rapid
developments in the clinical use of WES have required medical
geneticists to expand their competencies from clinical practice to
a variety of new skills, such as 'next-generation phenotyping' for
shortlisted exome candidates.7 In reality, the expertise required to
interpret these ﬁndings can no longer be harnessed by a single
professional.
The two major aims of this study are, ﬁrst, to report our ﬁndings
from an undiagnosed disease programme in a predominantly
Chinese population and validate whether the diagnostic yield is
indeed low. Second, we demonstrate the role of geneticists in the
post-exome review of WES reports, particularly in addressing
variants of uncertain signiﬁcance (VUSs).
RESULTS
Patient demographics and sequencing strategy
Among the 104 recruited subjects, 65 subjects were males, and
39 subjects were females; the median age at the time of
enrolment was four years and one month (range from one month
to 33 years). In total, WES of 81 patients (78%) were analysed as
singletons, and 23 patients (22%) were analysed as trios. Seventy-
nine patients (76%) were offered WES fully supported by study
funding, and the remaining patients paid either fully (n= 16) or
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partially (n= 9) out of pocket, i.e., the parents self-ﬁnanced their
own exomes, while the cost of sequencing of the proband was
supported. The overall average turnaround time for both
laboratories to provide the initial report was 20 weeks (range
from 3–39 weeks).
Indications for testing
The clinical presentations were classiﬁed according to the primary
indication for testing. A standard laboratory check list was used for
the exome requests, and the primary panel of genes analysed was
based on this indication. The most common indication for testing
was neurological disorders (67%), including intellectual disabilities
(n= 34), movement disorders (n= 12), neuromuscular diseases (n
= 11), mitochondrial diseases (n= 5) and epilepsy (n= 8). The
remaining indications included multiple congenital anomalies (n
= 17, 16%) or other suspected genetic disorders (n= 17, 16%)
(Supplementary Figure 1).
Diagnostic yield
Immediately after the targeted parental Sanger sequencing of the
singleton exomes, among all 104 cases, 26 cases (25%) were
classiﬁed as deﬁnitive (Category 1) diagnoses, and a clear
molecular diagnosis was established. The reanalysis by the
geneticist increased this yield by 12 cases, including 10 cases
that were promoted to deﬁnitive (Category 1), and two additional
variants were discovered (FGD1 and IGHMBP2) (Table 1). During
the duration of this project, the laboratory subsequently
reanalysed the WES data due to updated bioinformatics pipelines8
or newly published studies, and ﬁve additional diagnoses were
revealed in a supplementary report. These diagnoses included
pathogenic variants in PPP1CB,9 DDX3X10 and ASXL311 and two
copy-number variations, i.e. an 8-Mb loss of 10q26.2-qter and a
mosaic 33.89-Mb gain of 12p13.33-p11.1 (Pallister–Killian syn-
drome). Overall, a conclusive diagnosis was achieved in 43 cases
(41%) (Fig. 1). Excluding the two CNV diagnoses, of the 41 cases,
21 autosomal dominant (AD), 12 autosomal recessive (AR) and
eight X-linked (XL) diseases were diagnosed. Of these diseases, 24
(59%) cases were de novo mutations. Overall, 22 reports (51%)
involved novel mutations that have not been previously reported
(literature search was performed in May 2017). Three of these
novel missense variants were found in a codon that was also the
site of a different variant that had previously been reported as
pathogenic. These diagnoses included more well-known disease
genes (e.g. HRAS, ATRX, CREBBP, NTRK1, FANCA, UPB1, SBDS, SPG11,
STXBP1, AGRN, GRIN2A, CHKB and PACS1) and genes that have only
been reported recently (e.g. PURA, DDX3X, WAC, PPP1CB and
KMT2B), as shown in Table 2. All variants identiﬁed in this study are
summarised in Supplementary Table 1.
Number of cases requiring an extensive analysis
We calculated the time spent on the post-exome analysis as
described in the Methods. In total, 40 cases were negative reports,
which required no further input from the geneticist. Of the
remaining reports, 27 of the 104 (26%) cases required more than
3 h to review, reﬂecting the extensive workload. This in-depth
review by the clinical geneticist was particularly helpful in several
ways: (1) detailed review of conﬂicting interpretations of
pathogenicity in literature, (2) comparison of global and ethnic-
speciﬁc allele frequencies, (3) request of additional clinical
functional assays, and (4) correlation of molecular ﬁndings with
the clinical context.
Management implications of WES
Among all 43 positive diagnoses, 77% (n= 33) of the WES
diagnoses provided further information aiding clinical manage-
ment. This management could be based on disease-speciﬁc
published management guidelines, i.e. Category 1 (n= 13, 30%),
or case reports or the known function of genes, i.e. Category 2 (n
= 20, 47%) (Supplementary. Figure 2), utilising the classiﬁcation
adopted by Stavropoulos et al.12 Six major types of interventions
were classiﬁed according to Riggs et al.13 We observed that WES
most commonly aided management in the areas of surveillance
(53%) and specialist referral (44%) (Table 2 and Supplementary
Table 2). However, the implications on clinical outcomes are
difﬁcult to measure without an extensive longitudinal follow-up.
The details of the management changes are as follows:
i. A referral to a specialist was made in 19/43 (44%) cases after
the WES diagnosis. For example, a diagnosis of
Lenz–Majewski hyperostotic dwarﬁsm (LMHD) prompted
referrals to endocrinology for a DEXA scan and orthopaedics
for a skeletal assessment (U050).
ii. Further diagnostic testing was ordered in 16/43 (37%) cases.
In a patient (case U027) diagnosed with
Shwachman–Bodian–Diamond syndrome, exocrine pancrea-
tic dysfunction is a known anomaly in this condition, and by
ordering abdomen CT, evidence of pancreatic lipomatosis
was found. In another case (U084), the patient was
diagnosed with lower extremity-predominant spinal mus-
cular atrophy. Thus, an MRI of the leg muscle was ordered to
further elucidate the diagnosis and severity.
iii. Surgical or interventional procedures were indicated or
contraindicated after a genetic diagnosis was achieved in 3/
43 (7%) cases. In a patient with early-onset generalised
dystonia (U102), a mutation in KMT2B causing childhood-
onset dystonia was identiﬁed, leading to multiple beneﬁts
for counselling and management. First, the life expectancy
was reportedly extended into adulthood. Furthermore,
dopamine treatment for Parkinsonism was shown to be
ineffective,14 and the patient was referred for deep brain
stimulation after performing a literature review. In a case of
infantile Fanconi anaemia (complementation group A), the
genetic diagnosis led the paediatrician to arrange for
matched-sibling cord blood transplantation for the child at
the age of 13 months.
iv. Surveillance for potential complication(s) associated with
genetic variants was advised in 23/43 (53%) case. This
recommendation was the most common among all changes
in clinical management. For example, regular assessments
for developmental, ophthalmic, and intracranial manifesta-
tions were advised for children with NF1 mutations.15
v. Medication was indicated or contraindicated in 12/43 (28%)
patients. For example, a mutation in ARGN was identiﬁed in
a patient refractory to treatment with acetylcholinesterase
inhibitors for congenital myasthenia gravis (U092). The
option of treatment with salbutamol was prompted after a
review of the latest literature.16 The genetic diagnosis may
also ﬂag new contraindications for medications. In con-
genital megaconial muscular dystrophy associated with
CHKB variants, reports have suggested the possibility that
inter-current vaccinations or anaesthesia can lead to
deterioration in muscle or cardiac function; thus, extra
caution is advised.17
vi. Lifestyle changes were advised in 6/43 (14%) cases,
including sun protection against the potential complication
of squamous cell carcinoma in a patient with a mutation in
GJB2 or keratitis-ichthyosis-deafness syndrome.
DISCUSSION
The key aims of this study are to report our ﬁndings in a non-
Caucasian predominantly Han Chinese population (92%) and to
examine the role of medical geneticists in the diagnostic odyssey
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of WES, particularly in the post-exome analysis of laboratory
variant reports.
In this cohort of 104 patients, the overall diagnostic yield was
41% (n= 43), which is consistent with the previously reported
range of 25–57.7%.1–4 The Han Chinese population has been
under-represented in WES studies, but this population consti-
tutes the largest ethnic group worldwide.18 We provide further
data from this ethnic group to expand the spectrum of
molecular diagnoses achieved and to compare the diagnostic
yield. Although a direct comparison of diagnostic yield is
difﬁcult, particularly due to variations in the selection criteria,
our ﬁndings show that WES can be utilised in the Han Chinese
population with a yield comparable to that reported in major
studies.
Areas of post-exome analysis affecting outcome
Five key areas of the post-exome analysis led to a different clinical-
level classiﬁcation of the variants from the case-level classiﬁcation
derived from the laboratory data.
Post-exome phenotyping. Post-exome phenotyping can often be
helpful in reaching a more complete diagnosis, particularly when
the neurological proﬁle of paediatric patients changes over time
or the speciﬁc phenotypic features do not ﬁt the proposed
molecular diagnosis, e.g. a blended phenotype. For example, in a
patient diagnosed with Rubinstein–Taybi syndrome, a careful
examination revealed the presence of café au lait spots in both the
child and father. This suspicion led to a targeted reanalysis and the
discovery of a second genetic diagnosis involving the NF1 gene
(U039). In such cases, the geneticist’s proactive effort to review the
WES ﬁndings and effective communication with the laboratory
can facilitate a more comprehensive diagnosis.
Post-exome diagnostics. Various inherited diseases inevitably
require additional diagnostics to further conﬁrm the diagnosis.
These diagnostic assessments include additional clinical biochem-
ical and radiological tests, molecular diagnostic modalities, e.g.
Multiplex Ligation-dependent Probe Ampliﬁcation (MLPA), and
segregation of the variant allele within the extended family.
Examples of further clinical testing include (1) purines and
pyrimidines for beta-ureidopropionase deﬁciency (U023), (2) X-
inactivation studies and transferrin electrophoresis for X-linked
congenital disorder of glycosylation type II (U033), and (3) Hb H
inclusion bodies for alpha-thalassemia/mental retardation syn-
drome (U003).
An additional example of molecular diagnostic modalities
includes a single variant in IGHMBP2, which was reported in a
patient with suspected autosomal recessive Charcot–Marie–Tooth
disease. Due to a strong suspicion based on the phenotypic features,
the geneticist prompted the laboratory to search for other variants
in the gene. A second 83 bp deletion was conﬁrmed by Sanger
sequencing (U098) after the exome data were deemed suspicious.
In a few cases, segregation data of extended family members
may also help provide further evidence, particularly in families
with suspected AR diseases and multiple siblings.19 As described
by the ACMG guidelines for variant interpretation,20 the testing of
extended family members can strengthen or refute the patho-
genicity of the variants, such as in cases U029 (SPAST), U031
(PIGO), and U049 (ATP6V1A). This process is also best initiated by
the medical geneticist
Extensive database evaluation. The bulk of the time spent by the
geneticist involved an extensive review of the latest studies and
databases to identify novel variants.
In Hong Kong, the assessment of ethnic-speciﬁc variants has
been a challenge due to the lack of a large local variant database.
This situation has improved with the recent availability of ethnic-
speciﬁc exome aggregation data. For example, the homozygous
variant GJB2:p.(V37I) was initially classiﬁed as likely pathogenic
based on a WES report (U070). However, a manual search of the
variant in gnomAD identiﬁed 80 homozygous alleles exclusively in
East Asians. After discussion with the WES laboratory and various
experts, this variant was considered likely a hypomorphic allele
with a partial effect on hearing loss.
Another, more complicated example is the UPB1 (p.(R326Q))
variant. Despite the minor allele frequency of 2.5% in East Asians,
this variant has been reported multiple times as pathogenic in
Chinese and Japanese populations.21–23 In particular, Nakajima
et al.21 identiﬁed eight homozygotes among affected patients,
which was supported by functional studies showing a dramatically
reduced residual activity of the mutant βUP. We arranged for a
further urine test to measure the pyrimidine degradation
metabolites in our patient, and the pyrimidines were highly
elevated, e.g. the N-carbamyl-ß-amino acids were elevated from
the baseline of 0.50 to 16.65 (over a 30-fold increase). The
neurologist conﬁrmed that the phenotypic features of cerebella
atrophy and seizures were consistent with the diagnosis. This
patient was further discussed with an expert in inborn errors of
purine and pyrimidine metabolism, who also conﬁrmed the
pathogenicity of this variant.
Fig. 1 Change in classiﬁcation after reanalysis. The number of deﬁnitive diagnoses increased from n= 26 to n= 43. This was a result of both
laboratory (n= 5) and clinician (n= 12) initiated reanalysis. The number of both “negative” (n= 6) and “candidate” variants of uncertain
signiﬁcance (n= 9) was reduced. Therefore increasing the yield and reducing ambiguity
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Expert liaison. The process of involving other experts overseas
or discussing cases with specialists in the ﬁeld had the greatest
impact on the ﬁve key areas, and most cases in which the
interpretation was altered required discussion with relevant
experts (11/16, 69%). In the case of uncertainty, expert liaison is
often an effective strategy for clarifying the overall interpretation
and ﬁlling in the gaps in knowledge.
For example, in case U103, the exome was negative, and the
phenotype and photographs were reviewed with an expert in
dysmorphology. This review raised the suspicion of
Aarskog–Scott syndrome, and a molecular diagnosis was
identiﬁed by a targeted reanalysis of the FGD1 gene (U103).
Similarly, many cases involved experts in a relevant ﬁeld because
the experts are more proﬁcient at recognising relevant
phenotypes or mutational hot spots. For example, case U051
was a patient with myopathy, and a collagen disorder was
suspected; three VUSs were identiﬁed in the COL6A2 gene. The
involvement of an expert enabled a comprehensive assessment
of the clinical features, muscle biopsy results and molecular
ﬁndings. It was determined that the presentation did not ﬁt
known cases of COL6A2 myopathies, demoting this to an unlikely
genetic diagnosis.
Clinical functional assays. Functional tests are helpful in
conﬁrming the pathogenicity of variants and can be performed
through collaboration with other laboratories. Examples include
(i) ﬂow cytometry of patient granulocytes demonstrating GPI-
anchor deﬁciency24 for these novel variants in the PIGO gene
(U032) and (ii) reduced complex II+ III activity in ﬁbroblasts in a
patient with novel COQ4 variants (U028). The collaboration in
both cases was crucial for conﬁrming these novel variants as
pathogenic variants.
Cases requiring extensive time to review
The time required to review these reports greatly varied. We
highlight that 26% (n= 27) of all reports required an extensive
amount of time (>3 h) to review. Most cases were novel variants
which can be attributed to the fact that 24 diagnoses were in
genes discovered after the project was started in 2012. These
genes included ATP6V1A, PPP1CB, KMT2B, DDX3X, COQ4, WAC,
PTDSS1, PURA, IGHMBP2, ASXL3, SLC35A2, ZC4H2, PACS1, ARID1B,
ARID1A, PIGO, WDR45, DYNC1H1, GNAI3, SMARCA2, and DYRK1A.
More importantly, 21 diagnoses (49%) of novel mutations have
never been previously reported (Supplementary Table 1).
The abundance of newly described diseases and previously
unreported variants highlight the power of WES as a diagnostic
tool, but, simultaneously, extensive involvement by a geneticist
is required to reafﬁrm these ﬁndings. Therefore, geneticists and
non-specialists should be particularly aware of these scenarios
because more input from experts in genetics is likely required. In
more resourceful centres, the ideal model involves a multi-
disciplinary team to examine and interpret these variants.
However, in a setting where genetic expertise is limited, pursuing
these cases may not be sustainable in the long term, and
additional staff is required to ensure adequate service delivery.
This excessive workload will likely be exaggerated when the
option of WES is opened to non-genetic specialists, and an
accurate and comprehensive interpretation of novel variants
greatly depends on the genetic expertise of the clinical team.
The laboratory often does not have the information the
physician has, and it is not a simple matter of performing a
molecular analysis at the laboratory and then following up on
the variant in the clinical setting. This challenge is particularly
apparent when the laboratory and clinical teams are not
geographically co-located. This geographical separation results
in cross-talk by electronic communication, and the clinical team
must often perform an extensive analysis of the novel VUSs. InT
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cases of difﬁcult novel variants, the clinical team can simply
choose to accept these as VUSs, but the proactive effort to review
these variants can have a substantial impact, even if it only results
in 12% more diagnoses (12/104).
Study limitations
The limitations of this study include the relatively small cohort size
(n= 104), but this sample provides a good representation of the
load of WES cases observed over the period of four years. Notably,
the singleton exome strategy was used in 78% of the cohort. The
choice of a singleton strategy was due to ﬁnancial constraints, and
88 of the 104 cases were supported by the study funding. Certain
data suggest that singleton exome sequencing as a ﬁrst-tier test
outperforms standard care4; thus, we adopted this at our clinic.
While this practice can be a limitation to our study, many
laboratories accept singleton exomes. We found this practice to be
a feasible alternative for patients who cannot pay out of pocket for
the cost, but additional resources for the segregation analysis are
required. Another limitation is the use of two different laboratories
and the inclusion of six additional patients from Taiwan. In
practice, referrals consist of patients not only from Hong Kong but
also from mainland China and other parts of Southeast Asia. Thus,
we did not exclude the Taiwanese patients from our selection of
patients, and we believe that our sample is a realistic representa-
tion of Han Chinese patients seeking genetic diagnoses in the Asia
Paciﬁc region.
CONCLUSION
In our predominantly Han Chinese cohort, the overall diagnostic
yield of WES was 41%. This is comparable to that observed in
previous studies involving Caucasian populations. We found that
in-depth review by the clinical geneticist was most helpful in
several areas: (1) detailed review of conﬂicting interpretations of
pathogenicity in literature, (2) comparison of global and ethnic-
speciﬁc allele frequencies, (3) request of additional clinical
functional assays, and (4) correlation of molecular ﬁndings with
the clinical context. Clinical geneticists will likely make the most
impact by focusing on these aspects to improve the overall
interpretation of WES reports. For the same reasons, we found that
26% (n= 27) of WES reports required an extensive amount of time
(>3 h) for the geneticist to review. Therefore, clinical genetics
services should be aware of the additional workload created and
the extra resources required to deal with the demands created by
the use of WES.
MATERIALS AND METHODS
Patient recruitment
The Department of Paediatrics and Adolescent Medicine at the Queen
Mary Hospital is a tertiary referral centre afﬁliated with The University of
Hong Kong. The service includes the neighbouring Duchess of Kent
Children’s Hospital, which specializes in developmental paediatrics,
rehabilitation and paediatric neurology. Both in-patient and out-patient
clinical genetic consultations are available at these two hospitals. Most
patients are residents of Hong Kong or mainland China. In addition, six
patients from National Taiwan University Hospital were included in our
cohort. Overall, 94% of the patients were of self-reported Han Chinese
ethnicity.
Patients were prospectively recruited from November 2012 to Novem-
ber 2016 by referrals to the clinical genetics service for undetermined
diagnoses. The indications included neurological disorders, multiple
congenital anomalies and other clinical presentations with a strong
suspicion of a monogenic cause. WES was offered to patients meeting the
indications for testing outlined by ACMG.25 A medical geneticist assessed
all patients for inclusion, and patients with a clearly recognisable genetic
syndrome or condition were excluded from this study (targeted genetic
tests were ordered for these patients). Chromosomal microarray was
performed for all patients referred within the same hospital. This was also
strongly recommended for referrals from other hospitals.
Fig. 2 Strategy for geneticist review of exome sequencing reports. An overview of the analysis process by the geneticist. Singleton results ﬁrst
undergo targeted parental segregation to elicit the mode of inheritance. After this, a ‘post-exome analysis’ is performed by the medical
geneticist, consisting of 5 key areas of actions. Subsequent interpretation of variants may be fed back to the laboratory at any stage of the
process
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Notably, WES is not currently provided by any molecular laboratory in
the public health care system in Hong Kong during the study period; thus,
the samples were sent to laboratories overseas. All families were ﬁrst
offered a self-ﬁnanced trio WES at the clinic. When the families could not
afford this out of pocket expense, a singleton WES of the proband was
offered and supported by the study funding. This strategy of singleton
WES was chosen to maximise the utility of the limited funding resources.
Whole-exome sequencing
The exome sequencing was performed by two laboratories. Of all reports,
95 reports were analysed by Genome Diagnostics Nijmegen (Nijmegen,
Netherlands), and nine reports were analysed by Ambry Genetics (Aliso
Viejo, CA).
For the WES performed at Genome Diagnostics Nijmegen, the targets
were enriched using Agilent SureSelectXT (Agilent Technologies), and the
whole-exome sequencing was performed on an Illumina HiSeq platform
(BGI, Copenhagen, Denmark), followed by data processing using BWA
(read alignment) and GATK (variant calling). The variants were annotated
using the external laboratory’s in-house-developed pipeline. The variants
were prioritised using an in-house-designed ‘variant interface’ and manual
curation.13 For the WES performed at Ambry Genetics, the samples were
prepared using a SureSelect Target Enrichment System (Agilent Technol-
ogies) or SeqCap EZ VCRome 2.0 (Roche NimbleGen) and sequenced on an
Illumina HiSeq 2000 or 2500. The initial data processing, base calling,
alignments and variant calls were performed using various bioinformatics
tools at Ambry Genetics. The variant calls were annotated using the Ambry
Variant Analyzer tool (AVA)26 and ﬁltered using laboratory-devised
strategies.
Post-exome review by a medical geneticist
All WES reports received from the overseas laboratories were re-evaluated
by a medical geneticist regardless of the variant classiﬁcation (Fig. 2). The
steps can be summarised into the following ﬁve main categories: (I) post-
exome phenotyping of any changes in the phenotype or additional
features, i.e. blended phenotype; (II) post-exome diagnostics, such as
additional molecular tests, segregation studies of extended family
members or clinical biochemical and radiological investigations; (III)
extensive database evaluations, including ClinVar, HGMD, disease-speciﬁc
databases, and population frequency databases of ethnic-speciﬁc allele
frequencies, e.g. ExAC (http://exac.broadinstitute.org) or Taiwan biobank
(https://taiwanview.twbiobank.org.tw/); (IV) expert liaison for opinions
regarding potential diagnoses and collaboration for aggregation of cases;
and (V) functional experimental studies that can only be performed at
specialised research laboratories. If further work on the WES data was
required after this review process, the information was communicated to
the laboratory.
Case-level and clinical-level classiﬁcations
Baldridge et al.3 utilised the following three levels of variant classiﬁcations:
(1) variant level, (2) case level and (3) clinical level. A variant-level assertion
is a raw interpretation of the variant, whereas a case-level assertion is a
synthesis of all molecular data regarding a single subject by the laboratory.
Using the same deﬁnition, the WES reports from Ambry and Nijmegen in
this study did not clearly distinguish between the two. In most reports
from Nijmegen, the terms used to describe the likelihood of pathogenicity
included ‘probably the cause’ or ‘very likely to be the cause’ and were more
consistent with a case-level description by the same deﬁnition. Thus, only
the 'case level' and 'clinical level' were utilised in this study (Table 3). The
terms deﬁnitive (Category 1), possible (Category 2), candidate (Category 3)
and negative (Category 4) were used based on the WES reports. The
criteria used to determine the clinical-level classiﬁcation included the
phenotype-genotype correlation after discussion with experts; follow-up
biochemical, radiological and functional studies; and additional molecular
studies (e.g. X-inactivation). These criteria cannot be evaluated at the case-
level-based on the initial laboratory report. The term 'unlikely' (Category 4)
was used when a molecular diagnosis was deemed implausible after
review (Table 3). The ﬁndings were considered concordant between case
level and clinical level if the category was unchanged, e.g. deﬁnitive
(Category 1). When a difference existed between the two, the classiﬁcation
was considered discordant and was indicated as promoted or demoted
accordingly.T
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Targeted parental segregation analysis of singleton exome results
For the variants identiﬁed in the singleton WES, a targeted parental
segregation analysis was performed by Sanger sequencing. To avoid
confusion and for an equal comparison of the singleton and trio cases, the
case-level classiﬁcation was considered only after the segregation analysis.
Thus, variants conﬁrmed by parental segregation alone were not
considered a change in classiﬁcation due to the geneticist’s input.
Evaluation of the time required to analyse the exome reports
A retrospective evaluation of the time spent by the geneticist on the
analysis was performed to illustrate the proportion of cases requiring an
extended period of review. Cases requiring extensive discussion or follow-
up were deﬁned as those requiring well over three hours of work by the
geneticist and his research team. This time included time spent on
literature reviews, discussion among the research team, communication
with experts and arranging specialised tests. Such discussions, electronic
communication and test requests were documented and in total would
have required well over three hours of the geneticist’s time. A cut-off of
three hours was chosen because this cut-off was more clinically relevant
and less likely to be affected by recall bias (Supplementary Table 1).
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